BFM
AVTX icon

Boothbay Fund Management’s Avalo Therapeutics AVTX Stock Holding History

Boothbay Fund Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$663K Buy
+44,400
New +$694K 0.01% 1179

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Boothbay Fund Management's AVTX Position: Q1 2026 in Review

Boothbay Fund Management increased its Avalo Therapeutics (AVTX) stake by 60% in Q1 2026, buying an estimated $1.91M and bringing the position to 324,258 shares worth $4.84M. The position accounts for 0.06% of the portfolio, ranked #334.

Boothbay Fund Management first reported a position in AVTX in Q4 2017 and has held it in 22 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Boothbay Fund Management held 324,258 shares of Avalo Therapeutics worth $4.84M as of Q1 2026.
  • Boothbay Fund Management bought 122,131 Avalo Therapeutics shares in Q1 2026, an estimated $1.91M.
  • Avalo Therapeutics made up 0.06% of Boothbay Fund Management's portfolio in Q1 2026, its #334 holding.
  • Boothbay Fund Management first reported a position in Avalo Therapeutics in Q4 2017 and has held it in 22 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.